

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3933)**

### **PROFIT WARNING**

This announcement is made pursuant to Rule 13.09(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board wishes to inform the shareholders of the Company that the profit after taxation of the Group for the year ended 31 December 2011 is expected to decrease materially as compared with last year. The decrease is mainly due the restricted use of antibiotics medicines and the price reduction policy on the finished products launched by the government, continued drop in the prices of bulk medicine and intermediate products, and increase in finance costs as a result of rise of bank borrowing rates in second half of 2011.

**Shareholders of the Company and potential investors are advised to exercise caution in dealing in the shares of the Company.**

This announcement is made pursuant to Rule 13.09(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) (together with its subsidiaries, the “Group”) wishes to inform the shareholders of the Company that the profit after taxation of the Group for the year ended 31 December 2011 is expected to decrease materially as compared with last year. The decrease is mainly due the restricted use of antibiotics medicines and the price reduction policies on the finished products launched by the government, continued drop in the prices of bulk medicine and intermediate products, and increase in finance costs as a result of rise of bank borrowing rates in second half of 2011.

This profit warning announcement is only based on preliminary unaudited management accounts of the Group for the year ended 31 December 2011.

**Shareholders of the Company and potential investors are advised to exercise caution in dealing in the shares of the Company.**

By Order of the Board  
**The United Laboratories  
International Holdings Limited**  
Leung Wing Hon  
*Executive Director*

Hong Kong, 16 February 2012

As at the date of this announcement, the Board comprises Mr. Choy Kam Lok, Ms. Peng Wei, Mr. Leung Wing Hon, Mr. Tsoi Hoi Shan, Ms. Zou Xian Hong, Ms. Zhu Su Yan and Mr. Fang Yu Ping as executive directors; Ms. Choy Siu Chit as non-executive director; and Mr. Chong Peng Oon, Mr. Huang Bao Guang and Mr. Song Ming as independent non-executive directors.